Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.32 |
| ▸ | PPARG | P37231 | 7/20 | 0.32 |
| ▸ | PPARD | Q03181 | 7/20 | 0.32 |
| ▸ | PPARA | Q07869 | 7/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.32 |
| ▸ | TSHR | P16473 | 4/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | FABP4 | P15090 | 2/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5178373 | 0.94 | CES2 (0.38) | CES2GGPS1GPR84PPARGPPARD | |
| SCHEMBL5179328 | 0.92 | CES2 (0.39) | CES2GGPS1GPR84PPARGPPARD | |
| SCHEMBL4057603 | 0.92 | CES2 (0.39) | CES2GGPS1GPR84PPARGPPARD | |
| SCHEMBL5983660 | 0.92 | CES2 (0.39) | CES2GGPS1GPR84PPARGPPARD | |
| SCHEMBL2682265 | 0.92 | CES2 (0.39) | CES2GGPS1GPR84PPARGPPARD | |
| SCHEMBL5665231 | 0.92 | CES2 (0.39) | CES2GGPS1GPR84PPARGPPARD | |
| SCHEMBL9274885 | 0.90 | CES2 (0.36) | CES2GGPS1GPR84PPARGPPARD | |
| Acetic Acid SCHEMBL9376014 | 0.88 | MEN1 (0.35) | CES2GGPS1GPR84PPARGPPARD | |
| Acetic Acid SCHEMBL4292824 | 0.88 | MEN1 (0.35) | CES2GGPS1GPR84PPARGPPARD | |
| SCHEMBL15572971 | 0.87 | CES2 (0.40) | CES2GGPS1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194417-B1 | ENT-19-NORPROGESTERONE FOR USE IN THE TREATMENT OF TRAUMATIC BRAIN INJURY | PREVACUS INC (US) | 2020-10-28 | — | — | EP | disclosed |
| CN-105980396-B | The synthesis of enantiomerism-progesterone and its intermediate | 普瑞维卡斯有限公司 | 2019-03-22 | — | — | CN | disclosed |
| EP-3416651-A1 | C-20 STEROID COMPOUNDS, COMPOSITIONS, AND USES THEREOF TO TREAT TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSIONS | Prevacus, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| CN-107108689-A | C-20 steroid compounds, compositions thereof and use for treating Traumatic Brain Injury (TBI) including concussion | 普瑞维卡斯有限公司 | 2017-08-29 | — | — | CN | disclosed |
| EP-3194417-A1 | C-20 STEROID COMPOUNDS, COMPOSITIONS AND USES THEREOF TO TREAT TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSIONS | Prevacus, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016209847-A1 | C-20 STEROID COMPOUNDS, COMPOSITIONS, AND USES THEREOF TO TREAT TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSIONS | PREVACUS, INC. (US) | 2016-12-29 | — | — | WO | disclosed |
| CN-105980396-A | Synthesis of ent-progesterone and intermediates thereof | 普瑞维卡斯有限公司 | 2016-09-28 | — | — | CN | disclosed |
| US-20160168190-A1 | C-20 STEROID COMPOUNDS, COMPOSITIONS AND USES THEREOF TO TREAT TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSIONS | ORAGENICS, INC. | 2016-06-16 | — | — | US | disclosed |
| WO-2016044559-A1 | C-20 STEROID COMPOUNDS, COMPOSITIONS AND USES THEREOF TO TREAT TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSIONS | PREVACUS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20150175650-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | PREVACUS INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-6051713-A | USEFUL AS REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION, PARTICULARLY AS AGENTS FOR TREATING SKIN RELATED DISEASES, INCLUDING ACTINIC KERATOSES, ARSENIC KERATOSES, INFLAMMATORY AND NON-KERATINIZATION SKIN DISORDERS | ALLERGAN SALES, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-5965606-A | RETINOID RECEPTORS, 2-FLUORO-4-(2',2',4',4'-TETRAMETHYL-8'-TRIFLUOROMETHYLCHROMAN-6' -YL)CARBAMOYL BENZOIC ACID FOR TREATING MONOCYTIC LEUKEMIA | ALLERGAN SALES, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5917048-A | Substituted aryl or heteroarylamides having retinoid-like biological activity | ALLERGAN SALES INC. (US) | 1999-06-29 | — | — | US | disclosed |
| CN-1211180-A | Method of treatment with compounds having RAG 'alpha' receptor specific or selective activity | ALLERGAN CO (US) | 1999-03-17 | — | — | CN | disclosed |
| CN-1207727-A | Substd. aryl or heteroarylamides having retinoid-like biological activity | VISION PHARM LP (US) | 1999-02-10 | — | — | CN | disclosed |
| EP-0869782-A2 | METHODS OF TREATMENT WITH COMPOUNDS HAVING RAR $g(a)? RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY | Vision Pharmaceuticals L.P. (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0862555-A1 | SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5663357-A | COMPOUNDS FOR TREATMENT OF SKIN DISORDERS | ALLERGAN (US) | 1997-09-02 | — | — | US | disclosed |
| WO-1997024116-A2 | METHODS OF TREATMENT WITH COMPOUNDS HAVING RARα RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY | VISION PHARMACEUTICALS L.P. (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997019062-A1 | SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175650-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | CYP21A2, PGR, CYP17A1 | CES2 1996/4885GGPS1 22/4885GPR84 1926/4885 |
| US-20160168190-A1 | C-20 STEROID COMPOUNDS, COMPOSITIONS AND USES THEREOF TO TREAT TRAUMATIC BRAIN INJURY (TBI), INCLUDING CONCUSSIONS | CYP17A1, HSD17B7, FABP7 | CES2 747/4885GGPS1 2202/4885GPR84 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.